


# **INFLAMISTRAT BIOCHIP**

## EARLY DIAGNOSIS CAN MAKE A DIFFERENCE



# Biochip enables rapid and precise multianalyte detection from a single patient sample, utilising

a biomarker algorithm to offer a highly sensitive screen for inflammation stratification.



accurately identify and classify inflammatory states, triage,



Biochip monitors patient response to treatment in real time, enabling faster tailored clinical intervention.



Biochip improves patient outcomes through rapid and trials.



hospitals £3.3 million/year

## Data-Driven Risk Stratification

Studies have shown that clinicians can improve patient survival rates in acute respiratory distress syndrome (ARDS) patients by distinguishing between two consistently identified phenotypes.

It is crucial to identify the hyperinflammatory phenotype quickly so that clinicians can make informed decisions regarding patient management options, which are essential in improving survival.



Stratifies Into:

or



**Hyper**inflammatory



**Hypo**inflammatory

### **PROBLEM**

Current lab-based tests often require sample batching and have long turnaround times:

- 1 Delaying phenotype identification
- Escalating pressure on hospital resources
- Prolonging treatment initiation and/or adjustment
- Increasing morbidity and mortality rates

Increasing length of ICU stays

### **SOLUTION**

Patient Pathway with Evidence MultiSTAT











Patient presents with ARDS symptoms

Immediate testing with Evidence MultiSTAT

Aids rapid phenotype identification in 36 minutes

Tailored and targeted treatment plans

#### **Biomarkers**

Soluble Tumour Necrosis Factor Receptor 1 (sTNFR1)

Interleukin-6 (IL-6)

#### **Product Information**



Sample Type Plasma



Samples Per Cartridge



Sample Volume



**Result Type** Quantitative



Time to Result 36 Minutes